|
|
Continued advancement of DNasebased oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the year with $9.0 million of cash to fund operationsFRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 / Xenetic Biosciences, Inc. NASDAQ:XBIO "Xenetic" or the &qu... Lire le communiqué |
|
| |
|
| |
|
|
Company building growing body of preclinical data to guide pathway to first in human trial for DNasebased oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. NASDAQ:XBIO "Xenetic" or the "Company", a biopharmaceutical company focused on advancing innovative immuneoncology technologies addressing hard to treat cancers, today announc... Lire le communiqué |
|
| |
|
| |
|
|
Encouraging growing body of preclinical data guiding pathway to first in human trial for DNasebased oncology platformDriving development towards Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsContinuing partnering discussions to advance development of systemic DNase and DNaseArmored CAR T programsEnded the q... Lire le communiqué |
|
| |
|
| |
|
|
Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ETFRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc. NASDAQ:XBIO "Xenetic" or the "Company", a biopharmaceutical company focused on advancing innovative immuneoncology technologies addressing hard to treat oncol... Lire le communiqué |
|
| |
|
| |
|
|
XCARTTM continuing to advance toward INDenabling studies PolyXen® platform technology growing royalty stream through license agreement Closed the year with $18.2 million of cashFRAMINGHAM, MA / ACCESSWIRE / March 23, 2022 / Xenetic Biosciences, Inc. NASDAQ:XBIO "Xenetic" or the "Company", a bi... Lire le communiqué |
|
| |
|
| |
